Vicarious Surgical is a pre-revenue medical device company developing a single-port robotic surgical system — the Vicarious Surgical System — designed to perform minimally invasive soft tissue surgery through a single small incision in the abdomen. The system enters the body through a 1.8 cm port, deploying two robotic arms and a stereoscopic camera inside the patient. The core differentiating technology is a "decoupled actuator" architecture, which mechanically separates joint movement to enable smaller, more flexible arms with a broader range of motion than competing systems. Each instrument arm has nine degrees of freedom and 28 sensors for real-time feedback. The system is also designed to be mobile, allowing it to be shared across operating rooms rather than requiring dedicated space. The initial target indication is ventral hernia repair, with plans to expand to other abdominal and gynecological procedures. Vicarious Surgical's intended business model follows the surgical robotics "razor and blade" model — selling or placing the capital system with hospitals and ASCs, then generating recurring revenue from single-use disposable instrument arms and accessories on a per-procedure basis. The company has not yet received FDA authorization and has not been commercialized; its near-term milestone is achieving design freeze by end of 2026, which is a prerequisite for clinical trials and an eventual FDA De Novo classification request. The FDA has accepted the system into its Safer Technologies Program, providing expedited communications. The company is currently a pure R&D spend business with limited cash runway.